<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229977">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086138</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH066136</org_study_id>
    <secondary_id>U01MH066136</secondary_id>
    <secondary_id>DATR A4-GPX</secondary_id>
    <nct_id>NCT00086138</nct_id>
  </id_info>
  <brief_title>Depression in Alzheimer's Disease-2</brief_title>
  <acronym>DIADS-2</acronym>
  <official_title>Depression in Alzheimer's Disease (DIADS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether treating individuals with Alzheimer's disease
      and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people
      with Alzheimer's disease and to their families and caregivers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or
      identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks.
      Visits include neuropsychological testing. Caregivers are asked to are the patient on a
      Daily Affect Diary for 6 weeks during the study period. Telephone followup is done at weeks
      36 and 48. Both groups receive caregiver support/education.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression remission (measured by the Cornell Scale for Depression in Dementia) and a global response measure (mADCS-CGI measuring mood, activity enjoyment, neurovegetative function and depressive cognitions.)</measure>
    <time_frame>Measured at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden and Quality of Life</measure>
    <time_frame>Measured at Weeks 24, 36, and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Cognitive Functioning, Quality of Life</measure>
    <time_frame>Measured at Weeks 24, 36, and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive sertraline at a target dose of 100mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to sertraline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline (Zoloft)</intervention_name>
    <description>Sertraline: range of 25 to 125 mg per day for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo designed to mimic sertraline taken daily for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Ability of the participant, caregiver or surrogate to provide written informed
             consent.

          -  Dementia due to Alzheimer's disease

          -  Stable treatment for Alzheimer's disease

          -  Ability for the participant's caregiver to accompany the participant to study visits
             and participate in the study.

        Exclusion

          -  Presence of a brain disease that might otherwise explain the presence of dementia

          -  Clinically significant hallucinations or delusions

          -  Current treatment of antipsychotics, anticonvulsants, and other antidepressants,
             benzodiazepines, or other psychotropic medications

          -  Need for hospitalization or residence in a nursing facility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine G. Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2004</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Constantine G. Lyketsos</investigator_full_name>
    <investigator_title>Chairman, Bayview Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
